Literature DB >> 25381623

Serum Bcl-2 values in children with pulmonary hypertension.

Alper Akın1, Dursun Alehan, Hayrettin Hakan Aykan, Süheyla Özkutlu, Sema Özer, Tevfik Karagöz.   

Abstract

In this study, we aimed to assess levels of serum B cell lymphoma 2 (sBcl-2) in children, which has been implicated in the etiopathogenesis of pulmonary hypertension (PH), as well its association with tissue Doppler echocardiographic imaging (TDI) data and parameters used in the follow-up of PH. The sBcl-2 level was assessed in 35 children with PH (24 had eisenmenger syndrome, and 11 had idiopathic PH) and in 38 healthy children as controls. TDI was performed on 25 patients whose cardiac anatomy allowed the test. The respective sBcl-2 values in patients and controls were 35.69 ± 18.83 and 2.66 ± 7.95 ng/ml (p < 0.001). The sBcl-2 levels were significantly greater in the New York Heart Association (NYHA) functional class 3 patients than those in the NYHA class 2 patients (p = 0.033). The sBcl-2 value in patients who walked <475 m in the 6-min walk distance (6MWD) test was significantly greater than in those who walked ≥475 m (p = 0.038). The sBcl-2 level showed a negative correlation with ejection time measured at the septal anulus (p = 0.026) and a positive correlation with interventricular septum-Tei (p = 0.018). The results of this study showed for the first time that there is an increase in the levels of sBcl-2 as an inflammatory marker and that the sBcl-2 levels are associated with prognostic parameters in children with PH. Because sBcl-2 levels were greater in patients who walked <475 meters during the 6MWD test, we suggest 475 ms as the cut-off value for the 6MWD test to differentiate between a good and a bad prognosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25381623     DOI: 10.1007/s00246-014-1052-x

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  23 in total

Review 1.  The key role of apoptosis in the pathogenesis and treatment of pulmonary hypertension.

Authors:  Emin Gurbanov; Xiao Shiliang
Journal:  Eur J Cardiothorac Surg       Date:  2006-07-25       Impact factor: 4.191

Review 2.  Novel strategy for treatment of pulmonary arterial hypertension: enhancement of apoptosis.

Authors:  Jing-bin Huang; Ying-long Liu; Pei-wu Sun; Xiao-dong Lv; Kong Bo; Xiang-ming Fan
Journal:  Lung       Date:  2010-03-06       Impact factor: 2.584

3.  Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension.

Authors:  T C Yeo; K S Dujardin; C Tei; D W Mahoney; M D McGoon; J B Seward
Journal:  Am J Cardiol       Date:  1998-05-01       Impact factor: 2.778

4.  Stage-dependent activation of cell cycle and apoptosis mechanisms in the right ventricle by pressure overload.

Authors:  A Ecarnot-Laubriet; M Assem; F Poirson-Bichat; M Moisant; C Bernard; S Lecour; E Solary; L Rochette; J-R Teyssier
Journal:  Biochim Biophys Acta       Date:  2002-04-24

5.  Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis.

Authors:  K N Cowan; P L Jones; M Rabinovitch
Journal:  Circ Res       Date:  1999-05-28       Impact factor: 17.367

Review 6.  Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms.

Authors:  Kurt R Stenmark; Karen A Fagan; Maria G Frid
Journal:  Circ Res       Date:  2006-09-29       Impact factor: 17.367

7.  Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.

Authors:  M Colombel; F Symmans; S Gil; K M O'Toole; D Chopin; M Benson; C A Olsson; S Korsmeyer; R Buttyan
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

8.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

9.  Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer.

Authors:  G Fontanini; S Vignati; D Bigini; A Mussi; M Lucchi; C A Angeletti; F Basolo; G Bevilacqua
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

Review 10.  Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis.

Authors:  B Martin; M Paesmans; T Berghmans; F Branle; L Ghisdal; C Mascaux; A-P Meert; E Steels; F Vallot; J-M Verdebout; J-J Lafitte; J-P Sculier
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

View more
  3 in total

1.  Redox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary Hypertension.

Authors:  Victor Tseng; Roy L Sutliff; C Michael Hart
Journal:  Antioxid Redox Signal       Date:  2019-02-25       Impact factor: 8.401

Review 2.  Novel biomarkers for pulmonary arterial hypertension.

Authors:  Anjum Anwar; Gregoire Ruffenach; Aman Mahajan; Mansoureh Eghbali; Soban Umar
Journal:  Respir Res       Date:  2016-07-20

Review 3.  The changing face of pulmonary hypertension diagnosis: a historical perspective on the influence of diagnostics and biomarkers.

Authors:  Jenny L Hewes; Ji Young Lee; Karen A Fagan; Natalie N Bauer
Journal:  Pulm Circ       Date:  2020-02-04       Impact factor: 3.017

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.